Navigation Links
Genomas Presents Drug-Specific Genetic Determinants of Statin Safety and Efficacy at the XV International Symposium on Atherosclerosis
Date:6/15/2009

Data Being Used to Develop DNA-Guided Decision Support for Statin Prescription

BOSTON, June 15 /PRNewswire/ -- Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, announced its participation at the prestigious XV International Symposium on Atherosclerosis, a meeting held triennially by the International Atherosclerosis Society. Gualberto Ruano, MD, PhD, President of Genomas, will present "Physiogenomic Contours of Statin Safety and Efficacy," a clinical study examining the differences in response to statin drugs based on individual gene variations.

Statins offer effective strategies to reduce cardiovascular disease and improve survival. However, there are clinically relevant safety risks for some patients. Statin-induced neuro-myopathy (SINM) may present as muscle aches, cramps, weakness, and muscle injury. SINM is more frequent at the higher doses required for treating advanced heart disease, and varies in extent between individual statins and from patient to patient. In previously published studies, over 10% of statin patients experienced neuromuscular side effects, causing disruptions in daily life activities, and reduction in regimen adherence.

In this study, 442 outpatients treated with atorvastatin, rosuvastatin and/or simvastatin were studied in lipid clinics at Hartford Hospital (Hartford, CT) and the University of California, San Francisco. Researchers genotyped 384 SNPs (single nucleotide polymorphisms) from 222 cardiometabolic and neuroendocrine genes with a potential role in determining the safety and efficacy of statins. The study was funded in part by a grant from the National Institute of General Medical Sciences of the National Institutes of Health.

"Contrasting quantitatively how the gene polymorphisms associate with clinical responses, we visualize the 'physiogenomic contours' of statin drugs," said Dr. Ruano. "These contours represent the mechanistic differences among statins, which we plan to use as the foundation for DNA-guided rules for treatment on a patient-individualized basis."

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company is developing and testing revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes, and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit www.genomas.net for more information.


'/>"/>
SOURCE Genomas
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Latest trinational report presents most complete picture of North American industrial pollution
2. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
3. United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging
4. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
5. Frost & Sullivan Presents LG Electronics IRIS With the 2009 Global Iris Recognition Biometrics Market Customer Value Leadership of the Year Award
6. Sound Surgical Technologies Chief Technology Officer Presents Paper on Focused Ultrasound Technology
7. Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting
8. Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
9. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
10. Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook
11. AGA Institute presents cutting-edge research during DDW
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... ... of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly ... management information has been condensed to a single page, maximizing usability and improving ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video can get a jump ... winner will earn a $1,000 scholarship and have his or her video posted on ... deadline is May 31, with the winner announced on June 9. , The competition ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced this week ... Tranquility privacy panel system was designed to deliver the ideal blend of acoustic ... and provide the visual privacy required to maintain concentration levels and increase productivity. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Allegheny Health Network ... patients who seek access to the Network’s programs and services in the greater Pittsburgh ... specialty care appointments will be offered one for that same afternoon. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady Insurance Agency, a ... throughout eastern Georgia, is embarking on a charity effort to raise awareness and ... Americans every year than anything else, yet risk factors associated with heart disease ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ViewRay, Inc. (Nasdaq: VRAY) announced today that the ... in Germany , has purchased a ... University Clinic Heidelberg as part of its initiative for ... will be headed by Medical Director and Professor Jürgen ... the German Cancer Research Center (DKFZ), the Heidelberg Heavy ...
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
Breaking Medicine Technology: